Head-to-head evidence
SENL103 vs Zevorcabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
SENL103
Developed by Hebei Senlang Biotechnology
NCT06067581 · Phase 1 · status unknown
This is a small, uncontrolled, open-label Phase 1 dose-escalation study with no comparator arm, designed to find a safe dose of SENL103 CAR-T therapy in heavily pretreated myeloma patients. Efficacy is only a secondary measure and no results have been posted, so there is no evidence yet of a clinical effect.
Next expected readout: February 2028 · NCT07421856 (registry estimate)
Zevorcabtagene autoleucel
Marketed by CARsgen Therapeutics Holdings Limited
NCT03975907 · Phase 1/2 · status unknown
This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SENL103's landscape · Zevorcabtagene autoleucel's landscape